Adult Solid Tumor: Clinical Trials

26 trials for Adult Solid Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 4 terminated, 3 recruiting, 1 not yet recruiting. 11 Phase 1, 7 Phase 2, 3 Not applicable, 2 Phase 3, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 111Completed 5, Terminated 3, Not yet recruiting 1, Recruiting 1, Unknown 1
Phase 27Completed 4, Recruiting 2, Terminated 1
Not applicable3Completed 3
Phase 32Completed 1, Withdrawn 1
Early Phase 11Completed 1

Follow Adult Solid Tumor: new trials by email Literature Review of Adult Solid Tumor trials Research Report on Adult Solid Tumor

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab - Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Phase 2RecruitingCatalYm GmbH1312025-10-072026-10-26
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
Visugromab, Matching placebo for visugromab, Pembrolizumab 200 mg Q3W - Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Phase 2RecruitingCatalYm GmbH1072025-08-012026-10-19
A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor
LTC004 in Combination With Cyclophosphamide and Fludarabine - Adult Solid Tumor
Phase 1Not yet recruitingLetolab482024-03-012024-02-26
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
TT125-802 - Advanced Solid Tumor, Adult Solid Tumor
Phase 1CompletedTOLREMO therapeutics AG452023-11-072026-07-07
Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
Nivolumab, Visugromab (CTL-002), Placebo - Bladder Cancer, Adult Solid Tumor
Phase 2CompletedCatalYm GmbH312023-09-062026-08-19
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
DO-2 - Adult Solid Tumor, Advanced Solid Tumor
Phase 1RecruitingDeuterOncology552022-12-202026-04-03
Study of LTC004 in Subjects With Advanced Malignant Tumors
LTC004 - Adult Solid Tumor
Phase 1UnknownLetolab3682022-12-012022-12-28
Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor
HLX26, HLX10 - Adult Solid Tumor
Phase 1CompletedShanghai Henlius Biotech92022-07-262024-02-06
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ-eAPC-HPV, Pembrolizumab - Adult Solid Tumor
Phase 1 / Phase 2TerminatedSQZ Biotechnologies202022-03-242024-02-23
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
RP-6306 (oral PKMYT1 inhibitor) - Adult Solid Tumor
Phase 1TerminatedDebiopharm International SA672021-12-162025-12-05
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ-AAC-HPV, Ipilimumab, Nivolumab - Adult Solid Tumor
Phase 1TerminatedSQZ Biotechnologies52021-08-192024-02-23
Combining Epigenetic And Immune Therapy to Beat Cancer.
Durvalumab, Tazemetostat - Advanced Solid Tumor, Advanced Colorectal Carcinoma
Phase 2CompletedInstitut BergoniƩ1642021-07-232026-03-06
Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
Crofelemer 125 MG [Mytesi], Placebo - Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea
Phase 3CompletedNapo Pharmaceuticals, Inc.2872020-10-072024-07-26
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ-PBMC-HPV, Atezolizumab, Ipilimumab - Adult Solid Tumor
Phase 1CompletedSQZ Biotechnologies302020-01-282023-04-14
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
Refractory Cancer, Recurrent Cancer
CompletedImmatics US, Inc.2422019-02-262025-02-04
Hydrogen Gas for Cancer Rehabilitation
oxyhydrogen generator (AMS-H-03), analogue machine - Adult Solid Tumor
Not applicableCompletedFuda Cancer Hospital, Guangzhou302018-06-022020-10-19
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Pembrolizumab, Decitabine, Hypofractionated Index Site Radiation - Childhood Solid Tumor, Childhood Lymphoma
Early Phase 1CompletedChildren's Hospital Medical Center, Cincinnati222018-02-122026-02-18
Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence
stereotactic radiosurgery (SRS) - Brain Metastases, Adult Solid Tumor
Not applicableCompletedJuergen Debus2032018-02-012022-11-03
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
CANscript - Adult Solid Tumor
SuspendedMitra RxDx, Inc.8002017-07-132019-04-08
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Cancer, Adult Solid Tumor
TerminatedStrata Oncology582132016-11-012025-01-31

Showing 20 of 26. Sign in to see all of them.

Narrower conditions

Neoplasms (9)  ·  Recurrence (5)  ·  Breast Neoplasms (4)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Neoplasm Metastasis (4)  ·  Brain Neoplasms (3)  ·  Colorectal Neoplasms (3)  ·  Head and Neck Neoplasms (3)  ·  Lymphoma (2)  ·  Melanoma (2)  ·  Pancreatic Neoplasms (2)  ·  Salivary Gland Neoplasms (2)  ·  Sarcoma (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Urinary Bladder Neoplasms (2)

Broader conditions

Neoplasms by Site (10)  ·  Neoplasms (8)  ·  Neoplasms by Histologic Type (8)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Pathologic Processes (6)  ·  Disease Attributes (5)  ·  Urogenital Diseases (5)  ·  Urogenital Neoplasms (5)  ·  Breast Diseases (4)  ·  Bronchial Neoplasms (4)  ·  Carcinoma, Bronchogenic (4)  ·  Colonic Diseases (4)  ·  Digestive System Diseases (4)  ·  Digestive System Neoplasms (4)  ·  Endocrine Gland Neoplasms (4)

Interventions

Nivolumab (4)  ·  pembrolizumab (3)  ·  Docetaxel (2)  ·  Ipilimumab (2)  ·  AZD3965 (1)  ·  Bevacizumab (1)  ·  Cyclophosphamide (1)  ·  Decitabine (1)  ·  Dexmedetomidine (1)  ·  Gemcitabine (1)  ·  Hypericum extract LI 160 (1)  ·  Pemetrexed (1)  ·  Radiosurgery (1)  ·  Remifentanil (1)  ·  Saline Solution (1)

Sponsors

CatalYm GmbH (3)  ·  SQZ Biotechnologies (3)  ·  Letolab (2)  ·  Abramson Cancer Center at Penn Medicine (1)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Cancer Research UK (1)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  Debiopharm International SA (1)  ·  DeuterOncology (1)  ·  Fuda Cancer Hospital, Guangzhou (1)  ·  Hoffmann-La Roche (1)  ·  Immatics US, Inc. (1)  ·  Institut BergoniĆ© (1)  ·  Juergen Debus (1)  ·  Mitra RxDx, Inc. (1)

Countries

United States (16)  ·  Germany (5)  ·  Italy (4)  ·  Spain (4)  ·  China (3)  ·  France (3)  ·  Poland (3)  ·  Switzerland (3)  ·  United Kingdom (3)  ·  Belgium (2)  ·  Canada (2)  ·  Netherlands (2)  ·  Romania (2)  ·  Taiwan (2)  ·  Argentina (1)

Top investigators

Felix Lichtenegger, MD (2)  ·  Brian Turpin, DO (1)  ·  Cedrik Britten, M.D. (1)  ·  Charles P Theuer, MD (1)  ·  Eric Rowinsky, MD (1)  ·  Jaap Verweij, MD (1)  ·  Juergen Debus, Prof. Dr.Dr. (1)  ·  Lena Lemke, MD (1)  ·  Lionel D. Lewis, MD (1)  ·  Pablo Okhuysen, MD (1)  ·  Peter ODwyer (1)  ·  Pravin Chaturvedi, PhD (1)  ·  Ruth Plummer, Prof (1)  ·  Scott Tomlins, MD (1)

Results publications

PMID 25415228, PMID 25957999, PMID 29118225, PMID 31838007, PMID 31838015, PMID 31865734, PMID 32076124, PMID 32541132, PMID 32641862, PMID 32692450, PMID 33380580, PMID 33646820, PMID 34427452, PMID 34476329, PMID 34924145, PMID 36924196, PMID 38848521, PMID 39549678, PMID 40086048, PMID 40341199, PMID 41223704, PMID 41538111

NIH funding

2019 (1)